Yue J - Search Results

1

Phase-Transformation Nanoparticle-Mediated Sonodynamic Therapy: An Effective Modality to Enhance Anti-Tumor Immune Response by Inducing Immunogenic Cell Death in Breast Cancer.

Si Y, Yue J, Liu Z, Li M, Du F, Wang X, Dai Z, Hu N, Ju J, Gao S, Wang X, Yuan P. Si Y, et al. Among authors: yue j. Int J Nanomedicine. 2021 Mar 5;16:1913-1926. doi: 10.2147/IJN.S297933. eCollection 2021. Int J Nanomedicine. 2021. PMID: 33707946 Free PMC article.

2

Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer.

Lin S, Yue J, Guan X, Yuan P, Wang J, Luo Y, Fan Y, Cai R, Li Q, Chen S, Zhang P, Li Q, Ma F, Xu B. Lin S, et al. Among authors: yue j. Cancer Commun (Lond). 2019 Oct 11;39(1):57. doi: 10.1186/s40880-019-0399-z. Cancer Commun (Lond). 2019. PMID: 31601265 Free PMC article.

3

[An investigation of the fertility needs of young patients with breast cancer].

Ju J, Zhang LX, Yue J, Zhu AJ, Wang JY, Luo Y, Ma F, Zhang P, Li Q, Yuan P, Xu BH. Ju J, et al. Among authors: yue j. Zhonghua Zhong Liu Za Zhi. 2020 May 23;42(5):408-412. doi: 10.3760/cma.j.cn112152-112152-20191017-00672. Zhonghua Zhong Liu Za Zhi. 2020. PMID: 32482031 Chinese.

4

Impact of coronavirus disease 2019 on the clinical diagnosis and treatment of breast cancer in China.

Si YR, Du F, Hu NL, Wang X, Yue J, Jiang PD, Xu BH, Yuan P; Breast Cancer Group, Chinese Association for Clinical Oncologist. Si YR, et al. Among authors: yue j. Chin Med J (Engl). 2021 Feb 1;134(5):590-592. doi: 10.1097/CM9.0000000000001347. Chin Med J (Engl). 2021. PMID: 33528219 Free PMC article. No abstract available.

5

A Phase II, Single-Arm Study of Apatinib and Oral Etoposide in Heavily Pre-Treated Metastatic Breast Cancer.

Hu N, Zhu A, Si Y, Yue J, Wang X, Wang J, Ma F, Xu B, Yuan P. Hu N, et al. Among authors: yue j. Front Oncol. 2021 Feb 15;10:565384. doi: 10.3389/fonc.2020.565384. eCollection 2020. Front Oncol. 2021. PMID: 33659204 Free PMC article.

6

Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer.

Hu N, Si Y, Yue J, Sun T, Wang X, Jia Z, Gao S, Li Q, Shao Y, Wang J, Luo Y, Ma F, Xu B, Yuan P. Hu N, et al. Among authors: yue j. Cancer Biol Med. 2021 Mar 12;18(3):849-59. doi: 10.20892/j.issn.2095-3941.2020.0463. Online ahead of print. Cancer Biol Med. 2021. PMID: 33710812 Free PMC article.

7

Expression and clinical prognostic value of m6A RNA methylation modification in breast cancer.

Zheng F, Du F, Qian H, Zhao J, Wang X, Yue J, Hu N, Si Y, Xu B, Yuan P. Zheng F, et al. Among authors: yue j. Biomark Res. 2021 Apr 29;9(1):28. doi: 10.1186/s40364-021-00285-w. Biomark Res. 2021. PMID: 33926554 Free PMC article.

8

Phase II study of apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative metastatic breast cancer and clinical implications of monitoring ctDNA.

Zhu A, Yuan P, Hu N, Li M, Wang W, Wang X, Yue J, Wang J, Luo Y, Ma F, Zhang P, Li Q, Xu B, Cao S, Lippi G, Naito Y, Osman MA, Marta GN, Franceschini G, Orlandi A. Zhu A, et al. Among authors: yue j. Cancer Biol Med. 2021 May 26;18(3):875-87. doi: 10.20892/j.issn.2095-3941.2020.0418. Online ahead of print. Cancer Biol Med. 2021. PMID: 34037346 Free PMC article.

9

[Evaluation of the efficacy and safety of combination of gemcitabine and nedaplatin for patients with HER-2 negative metastatic breast cancer].

Yue J, Hu NL, Wang X, Si YR, Gao SL, Zheng FC, Ju J, Yuan P. Yue J, et al. Zhonghua Zhong Liu Za Zhi. 2021 Aug 23;43(8):883-888. doi: 10.3760/cma.j.cn112152-20200809-00723. Zhonghua Zhong Liu Za Zhi. 2021. PMID: 34407596 Chinese.

10

Updated efficacy of adjuvant epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes in early triple-negative breast cancer in phase 2 trial: 8.1-year median follow-up.

Zheng F, Du F, Wang W, Wang Y, Li M, Zhao J, Wang X, Yue J, Wang J, Yang Z, Cai R, Ma F, Fan Y, Li Q, Zhang P, Xu B, Yuan P. Zheng F, et al. Among authors: yue j. Breast Cancer Res Treat. 2022 Jan;191(1):97-105. doi: 10.1007/s10549-021-06401-6. Epub 2021 Oct 14. Breast Cancer Res Treat. 2022. PMID: 34648118 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

3,211 results

Search Page